The world's first vaccine against dengue, developed by French drugmaker Sanofi, has shown the ability to protect against disease caused by three of four dengue virus strains in a keenly awaited clinical trial in Thailand.
Sanofi said on Wednesday the proof of efficacy was "a key milestone" in the 70-year quest to develop a viable dengue shot, adding the results also confirmed the safety profile of the vaccine candidate.
The mosquito-borne disease - also known as "breakbone fever" - is a threat to nearly 3 billion people and is caused by four different types of virus, none of which confers immunity from the others.
Sanofi's vaccine generated an antibody response for all four dengue virus types, but evidence of protection was only demonstrated against three of the four circulating in Thailand. Sanofi said researchers were carrying out analyses to understand the lack of protection for the fourth serotype.
The company's vaccine unit, Sanofi Pasteur, has already invested 350 million euros ($423 million) in a new French factory to make the three-dose vaccine and believes its product could generate 1 billion euros in yearly sales.
But uptake of the vaccine will depend on precisely how well doctors believe it can protect populations at risk in fast-expanding tropical cities from Rio to Manila, as well as travelers.
Sanofi gave no details on the level of protection in a brief statement. The full data are now being reviewed by scientific experts and public health officials, with detailed results to be published later this year.
Sanofi previously said it planned to present the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.
Large-scale late-stage Phase III clinical studies with 31,000 participants are under way with Sanofi's vaccine in 10 countries in Asia and Latin America.
Located in the bustling Adjame quarter of Ivory Coast's main city and commercial hub, the haven for fake medicine has been targeted time and again by authorities and stockpiles burnt.
Seven firms to receive ecolabel certifying that their products are environment-friendly
Disasters saddle U.S. with $306 billion price tag, cause 362 deaths
Association for Prevention of Drug Abuse head says close to more than 2.5 million children are drug addicts in Bangladesh
King penguins are certainly accustomed to chilly weather, more so than species like the Humboldt that prefer somewhat warmer climes, said zoo curator Malu Celli.
Some eight million children and teenagers across the Southeast Asian nation will receive the shot to prevent further spread of the disease which is caused by a bacterial infection.
Two players vomited on the pitch, and play had to be halted briefly.
French pharmaceutical giant Sanofi announced Wednesday that its world-first dengue vaccine could lead to more severe symptoms for people who had not previously been infected.
Doctors Worldwide Turkey says it has performed 3,000 cataract surgeries in Horn of Africa country
Over 40,000 cases of cholera seen in Democratic Republic of Congo since July, says Health Ministry
Decked out in red to signify their "Stop Coal" campaign, the protesters chanted and beat drums as they snaked through the former West Germany capital toward the UN centre that will host the 12-day, 196-nation talks, tasked with implementing the landmark Paris Agreement.
The Greenhouse Gas Bulletin, the UN weather agency's annual flagship report, tracks the continent of dangerous gasses in atmosphere in the post-industrial era (since 1750).
£10 ($13) tax introduced to cut British capital's poor air-pollution records
Despite all-out efforts to give the Chinese Communist Party blue skies for its twice-a-decade congress, Beijing's notorious smog has cloaked the mega-city in its trademark toxic haze.
Equipment donation to children's oncology institute is first project of state-run aid agency TIKA in Brazil
Some 450 other suspected cases seen in island nation; president says health workers are able to contain epidemic